Navigating Next-Generation Cellular Therapies - The 7investing Podcast 7investing
Stock Tips Mobile Menu Dropdown Icon

Navigating Next-Generation Cellular Therapies

Lead Advisor Manisha Samy sits down with the Senior Vice President of Corporate Strategy and Finance of Cellectis, Simon Harnest, to discuss the complexities of creating an allogeneic approach for developing CAR-T therapies, especially for solid tumors. Simon addresses why Cellectis is up for the challenge. He also addresses the discrepancy between current valuations of Cellectis and competitor, Moderna (MRNA) who happens to license from Cellectis.

February 3, 2021 – By Samantha Bailey

The first chimeric antigen T-Cell Therapy (CAR-T) therapies were approved by the Federal Drug Administration (FDA) in 2017–these were heralded as “cures” for blood-borne cancers such as acute myeloid leukemia and aggressive non-Hodgkin’s Lymphoma.

Here, we have Simon Harnest, the Senior Vice President of Corporate Strategy and Finance of Cellectis (CLLS), unpacking where cell therapy is headed towards. Cellectis is the first company  to envision an “off-the-shelf” approach to CAR-T therapy. Previous methods required long manufacturing times and complex methodologies to create a single treatment for a patient.

In this episode, Simon guides us through the complexities of creating an allogeneic approach for developing CAR-T therapies, especially for solid tumors, and addresses why Cellectis is up for the challenge. He also addresses the discrepancy between current valuations of Cellectis and competitor, Allogene who happens to license from Cellectis.

This podcast is for anyone interested in learning about the nitty gritty of next generation cancer care from the bottom-up perspective.

 

Recent Episodes

Long-Term Investing Ideas in a Volatile Market

Simon recently spoke with a $35 billion global asset manager about how they're navigating the market volatility. The key takeaways are to think long term, tune out the noise...

Wreck or Rebound – Part 3! With Anirban Mahanti, Matt Cochrane...

Anirban and Matthew were joined by Alex Morris, creator of the TSOH Investment Research Service, to look at seven former market darlings that have taken severe dives from...

No Limit with Krzysztof and Luke – Episode 5

On episode 5 of No Limit, Krzysztof won’t let politics stand in the way of a good discussion - among many other topics!